Tinsley SM, Grande C, Olson K, Plato L, Jacobs I. Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology. J Adv Pract Oncol. 2018;9(7):699–716. https://doi.org/10.6004/jadpro.2018.9.7.2.

Article  PubMed  PubMed Central  Google Scholar 

Karateev D, Belokoneva N. Evaluation of physicians’ knowledge and attitudes towards biosimilars in Russia and issues associated with their prescribing. Biomolecules. 2019;9:1–16. https://doi.org/10.3390/biom9020057.

CAS  Article  Google Scholar 

Ilham M, Hafidz A, Jayaraman T, Affendi R, Ali R, Lee YY. Are we ready for biosimilars in gastroenterology? EMJ Gastroenterol. 2017;6(1):83–9.

Google Scholar 

World Health Organization. Report on the expert consultation on improving access to and use of similar biotherapeutic products. 2017;1–25. https://www.who.int/medicines/access/biotherapeutics/FINAL_Report-improving-access-to-and-use-of-biotherapeutics_October2017.pdf. Accessed 20 Aug 2021.

Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. J Intern Med. 2016;279:41–59. https://doi.org/10.1111/joim.12432.

CAS  Article  PubMed  Google Scholar 

Kabir ER, Moreino SS, Siam MKS. The breakthrough of biosimilars: a twist in the narrative of biological therapy. Biomolecules. 2019;9:1–34. https://doi.org/10.3390/biom9090410.

CAS  Article  Google Scholar 

European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) (CHMP/BMWP/42832/2005 Rev 1). 2014. p. 1–13. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-0.pdf. Accessed 22 Aug 2021.

Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, et al. Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts. Biomed Res Int. 2018;2018:9597362. https://doi.org/10.1155/2018/9597362.

Article  PubMed  PubMed Central  Google Scholar 

Nabhan C, Valley A, Feinberg BA. Barriers to oncology biosimilars uptake in the United States. Oncologist. 2018;23:1261–5. https://doi.org/10.1634/theoncologist.2018-0066.

Article  PubMed  PubMed Central  Google Scholar 

Yang J, Blinzler K, Lankin J, Vijayakumar S, Maculaitis MC, Shelbaya A. Evolving perceptions, utilization, and real-world implementation experiences of oncology monoclonal antibody biosimilars in the USA: perspectives from both payers and physicians. BioDrugs. 2022;36:71–83. https://doi.org/10.1007/s40259-021-00509-3.

CAS  Article  PubMed  Google Scholar 

Aitken M, Kleinrock M. Biosimilars in the United States, 2020-2024. Biotechnol Law Rep. 2020. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/iqvia-institute-biosimilars-in-the-united-states.pdf?_=1632381810556. Accessed 1 Apr 2022.

Kolbe AR, Kearsley A, Merchant L, Temkin E, Patel A, Xu J, et al. Physician understanding and willingness to prescribe biosimilars: findings from a US national survey. BioDrugs. 2021;35:363–72. https://doi.org/10.1007/s40259-021-00479-6.

Article  PubMed  Google Scholar 

Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE. 2017;12:1–17. https://doi.org/10.1371/journal.pone.0190147.

CAS  Article  Google Scholar 

Oskouei ST, Kusmierczyk AR. Biosimilar uptake: the importance of healthcare provider education. Pharmaceut Med. 2021;35:215–24. https://doi.org/10.1007/s40290-021-00396-7.

Article  PubMed  PubMed Central  Google Scholar 

Inotai A, Prins CPJ, Csanádi M, Vitezic D, Codreanu C, Kaló Z. Is there a reason for concern or is it just hype? A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther. 2017;17(8):915–26. https://doi.org/10.1080/14712598.2017.1341486.

Article  PubMed  Google Scholar 

Tieu C, Lucas EJ, DePaola M, Rosman L, Alexander GC. Efficacy and safety of biosimilar insulins compared to their reference products: a systematic review. PLoS ONE. 2018;13:1–14. https://doi.org/10.1371/journal.pone.0195012.

CAS  Article  Google Scholar 

Ebbers HC, Pieper B, Issa A, Addison J, Freudensprung U, Rezk MF. Real-world evidence on etanercept biosimilar SB4 in etanercept-naïve or switching patients: a systematic review. Rheumatol Ther. 2019;6(3):317–38. https://doi.org/10.1007/s40744-019-00169-4.

Article  PubMed  PubMed Central  Google Scholar 

Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734–55. https://doi.org/10.1002/cpt.1836.

Article  PubMed  PubMed Central  Google Scholar 

Sarnola K, Merikoski M, Jyrkkä J, Hämeen-Anttila K. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10(5): e034183. https://doi.org/10.1136/bmjopen-2019-034183.

Article  PubMed  PubMed Central  Google Scholar 

Giuliani R, Tabernero J, Cardoso F, McGregor KH, Vyas M, De Vries EGE. Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open. 2019;4(2):1–9. https://doi.org/10.1136/esmoopen-2018-000460.

Article  Google Scholar 

Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102–12. https://doi.org/10.18553/jmcp.2019.25.1.102.

Article  PubMed  Google Scholar 

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339: b2700. https://doi.org/10.1136/bmj.b2700.

Article  PubMed  PubMed Central  Google Scholar 

Rehman K, Bukhari NI, Babar ZUD. Equitable access to high-cost pharmaceuticals. 1st ed. New York: Academic Press; 2018.

Google Scholar 

Ruiz S. Biosimilars in the EU. Biosimilar Drug Prod Dev. 2017;395–411. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 15 Aug 2021.

O’Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol. 2019;75:1–11. https://doi.org/10.1007/s00228-018-2542-1.

Article  PubMed  Google Scholar 

Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Checklist for analytical cross sectional studies. Joanna Briggs Inst Rev Man. 2017;1–7. http://joannabriggs.org/research/critical-appraisal-tools. Accessed 25 Aug 2021.

Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):1–11. https://doi.org/10.1186/s40779-020-00238-8.

Article  Google Scholar 

Makhlouf SM, Pini S, Ahmed S, Bennett MI. Managing pain in people with cancer: a systematic review of the attitudes and knowledge of professionals, patients, caregivers and public. J Cancer Educ. 2020;35(2):214–40. https://doi.org/10.1007/s13187-019-01548-9.

Article  PubMed  Google Scholar 

Critical Appraisal Skills Programme. CASP qualitative studies checklist. 2018. https://casp-uk.b-cdn.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf. Accessed 27 Aug 2021.

Ricoy-Cano AJ, Obrero-Gaitán E, Caravaca-Sánchez F, La F-R. Factors conditioning sexual behavior in older adults: a systematic review of qualitative studies. J Clin Med. 2020;9(6):1716. https://doi.org/10.3390/jcm9061716.

Article  PubMed Central  Google Scholar 

Tanabe K, Sugimoto N, Fujimoto Y. A web-based survey to investigate the extent of awareness and understanding for biosimilar among Japanese physicians and pharmacists. Value Health. 2015;18(7):A658. https://doi.org/10.1016/j.jval.2015.09.2381.

Article  Google Scholar 

Almalki ZS, Iqbal MS, Alossaimi MA, Alsaber Z, Alanazi RA, Alruwaili YM, et al. Pharmacists’ awareness and perceptions of biosimilars in Saudi Arabia. 2020;14(3):3–6. https://doi.org/10.22377/ajp.v14i03.3757.

Article  Google Scholar 

Alahmari AK, Almalki ZS, Shahid Iqbal M, Alossaimi MA, Mohammed Zaid Alsaber M, Alanazi RA, et al. Knowledge and attitude of pharmacists about biosimilar medications in Saudi Arabia. Int J Pharm Investig. 2021;11(1):123–6. https://doi.org/10.5530/ijpi.2021.1.23.

Article  Google Scholar 

Foreman E, Patel H, Siderov J, Harchowal J, Bubalo J, Chan A. A survey of global biosimilar implementation practice conducted by the International Society of Oncology pharmacy practitioners. J Oncol Pharm Pract. 2020;26:22–32. https://doi.org/10.1177/1078155220913098.

Article  PubMed  Google Scholar 

Marín-Jiménez I, Carrascosa J, Guigini M, Monte-Boquet E. Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: a national survey. Farm Hosp. 2021;45:240–6. https://doi.org/10.7399/fh.11662.

Article  PubMed  Google Scholar 

Mhiri A, Khemakhem M, Kalboussi N, Kacem B. Knowledge and perceptions of biosimilar medicines by health professionals in Tunisia. Ann Pharm Françaises. 2021. https://doi.org/10.1016/j.pharma.2021.08.001.

Article  Google Scholar 

Tomaszewski D. Biosimilar naming conventions: pharmacist perceptions and impact on confidence in dispensing biologics. J Manag Care Spec Pharm. 2016;22:919–26. https://doi.org/10.18553/jmcp.2016.22.8.919.

Article  PubMed  Google Scholar 

Aladul MI, Fitzpatrick RW, Chapman SR. Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study. BMJ Open. 2018;8(11):1–8. https://doi.org/10.1136/bmjopen-2018-023603.

Article  Google Scholar 

Olave M, Lavery C, Leonard CE, Lo Re III V, Shea JA, Kay J, et al. Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs Ther Perspect. 2021;37:338–46. https://doi.org/10.1007/s40267-021-00844-z.

Article  PubMed  PubMed Central  Google Scholar 

Chan A, Patel H, Siderov J, Bubalo J, Foreman E. Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: an ISOPP membership survey. J Oncol Pharm Pract. 2020;26(3_Suppl.):11–21. https://doi.org/10.1177/1078155219898510.

Article  PubMed  Google Scholar 

Łukasik ZM, Nowicki M. Knowledge and attitude of community pharmacy employees towards an automatic drug substitution of generics and biosimilars. Acta Pol Pharm Drug Res. 2018;75(5):1247–54. https://doi.org/10.32383/appdr/85315.

Article  Google Scholar 

Paczkowska A, Kuś K, Kopciuch D, Zaprutko T, Stachowiak Z, Ratajczak P, et al. Safety of biodrugs: pharmacistsí knowledge and practice with regard to polish and European legal aspects and substitution of biotechnology drugs: multicenter study in Poland. Acta Pol Pharm Drug Res. 2020;77(4):657–64. https://doi.org/10.32383/appdr/127257.

Article  Google Scholar 

Chapman SR, Fitzpatrick RW, Aladul MI. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. BMJ Open. 2017;7(6):1–8. https://doi.org/10.1136/bmjopen-2017-016730.

Article  Google Scholar 

O’Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, et al. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: a survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017;88:252–61. https://doi.org/10.1016/j.yrtph.2017.06.013.

Article  PubMed